Attralus Receives European Medicines Agency Committee for Orphan Medicinal Products (COMP) Positive Opinions for AT-02 for the Treatment of Both ATTR and AL Amyloidosis

Jul 29, 2024 Press Releases

PDF Version AT-02 has been granted COMP positive opinions for orphan medicinal product designations in the EU for both ATTR and AL amyloidosis. AT-02 is the Company’s lead pan-amyloid removal therapeutic candidate in development. AT-02 is currently being evaluated in...

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)

May 30, 2024 Press Releases

PDF Version AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients to support its use as an immunotherapy in patients...

Clinical Trial Design of AT-02 Phase 2 Open-Label Extension Study in Systemic Amyloidosis

May 29, 2024 Posters & Publications

Click Here to View...

Characterization of the Peptide-Antibody Fusion, AT-02- Studies to Support its Use as an Immunotherapy in Patients with Amyloidosis

May 27, 2024 Posters & Publications

Click Here to View...

Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

Oct 17, 2022 Press Releases

PDF Version SAN FRANCISCO, Calif. – October 17, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the first subject has been dosed in...